1.4. Analysis.
Comparison 1: Ivermectin for treating COVID‐19 in inpatient settings with moderate to severe disease, Outcome 4: Serious adverse events during the study period
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.